ALK gene rearrangement positive

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
3 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Kinase inhibitor 1 substance
Platinum compound 1 substance
Antimetabolite 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    BRIGATINIB; CARBOPLATIN; PEMETREXED
    2023-510387-13-00 1 country 2022 n=110
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Intergroupe Francophone De Cancerologie Thoracique Academic 1 Phase II 0
New trials by year
2022
1
← All indication landscapes